Revenue Breakdown
Composition ()
No data
Revenue Streams
Profitability & Margins
Evaluating the bottom line, NewAmsterdam Pharma Company NV maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -15845.69%, while the net margin is -20691.09%. These profitability ratios, combined with a Return on Equity (ROE) of -39.94%, provide a clear picture of how effectively NAMS converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, NAMS competes directly with industry leaders such as VKTX and LGND. With a market capitalization of $3.52B, it holds a significant position in the sector. When comparing efficiency, NAMS's gross margin of 100.00% stands against VKTX's N/A and LGND's 89.70%. Such benchmarking helps identify whether NewAmsterdam Pharma Company NV is trading at a premium or discount relative to its financial performance.
